Key points are not available for this paper at this time.
Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available.
Reisberg et al. (Wed,) studied this question.